HK1200168A1 - Meldrum s acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors hno - Google Patents

Meldrum s acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors hno

Info

Publication number
HK1200168A1
HK1200168A1 HK15100597.0A HK15100597A HK1200168A1 HK 1200168 A1 HK1200168 A1 HK 1200168A1 HK 15100597 A HK15100597 A HK 15100597A HK 1200168 A1 HK1200168 A1 HK 1200168A1
Authority
HK
Hong Kong
Prior art keywords
hno
acid
meldrum
hydroxylamine
donors
Prior art date
Application number
HK15100597.0A
Other languages
English (en)
Chinese (zh)
Inventor
Daryl A Guthrie
John P Toscano
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of HK1200168A1 publication Critical patent/HK1200168A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D231/08Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • C07D231/22One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • C07D239/62Barbituric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/061,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15100597.0A 2011-10-17 2015-01-19 Meldrum s acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors hno HK1200168A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548036P 2011-10-17 2011-10-17
PCT/US2012/060425 WO2013059194A1 (en) 2011-10-17 2012-10-16 Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors

Publications (1)

Publication Number Publication Date
HK1200168A1 true HK1200168A1 (en) 2015-07-31

Family

ID=47143299

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100597.0A HK1200168A1 (en) 2011-10-17 2015-01-19 Meldrum s acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors hno

Country Status (13)

Country Link
US (3) US9181213B2 (xx)
EP (1) EP2776402B1 (xx)
JP (1) JP6177246B2 (xx)
KR (1) KR102061537B1 (xx)
CN (2) CN104053647B (xx)
AU (2) AU2013201929B2 (xx)
BR (1) BR112014009282B1 (xx)
CA (1) CA2852914C (xx)
HK (1) HK1200168A1 (xx)
IL (1) IL232101A (xx)
MX (1) MX363306B (xx)
SG (1) SG11201401587QA (xx)
WO (1) WO2013059194A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、hno供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
JP6449171B2 (ja) 2013-01-18 2019-01-09 カルディオキシル ファーマシューティカルズ,インク. 治療指数の改善されたニトロキシル供与体
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
US9682938B2 (en) * 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
US9464061B2 (en) * 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
ES2871079T3 (es) * 2015-06-26 2021-10-28 Univ Johns Hopkins Acidos hidroxámicos N-sustituidos con grupos salientes a base de carbono como donantes eficaces de HNO y usos de los mismos
KR20180070672A (ko) 2015-10-19 2018-06-26 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여자로서의 n-히드록실술폰아미드 유도체
US10723704B2 (en) 2015-10-19 2020-07-28 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
JP7194436B2 (ja) * 2016-07-28 2022-12-22 ザ ジョンズ ホプキンス ユニバーシティ O-置換ヒドロキサム酸
WO2018128999A1 (en) 2017-01-03 2018-07-12 Cardioxyl Pharmaceuticals, Inc. Method of administering nitroxyl donating compounds
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US11912647B2 (en) 2020-05-22 2024-02-27 University Of Georgia Research Foundation, Inc. Diversity-oriented synthesis of N,N,O-trisubstituted hydroxylamines from alcohols and amines by N—O bond formation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
BR9812982A (pt) 1997-10-24 2000-08-08 Shionogi & Co Agente anti-reumático
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6638534B1 (en) 1998-07-28 2003-10-28 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
EP1718621A4 (en) 2004-01-30 2009-08-19 Univ Johns Hopkins NITROXYL PREPARATION COMPOUNDS APPLICATION METHOD
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
JP2008543947A (ja) 2005-06-23 2008-12-04 ジョンズ ホプキンス ユニバーシティ チオール感受性の正の変力物質
WO2007109175A1 (en) 2006-03-17 2007-09-27 Johns Hopkins University School Of Medicine N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US7696373B2 (en) 2006-04-13 2010-04-13 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
KR101905004B1 (ko) 2007-09-26 2018-10-08 존스 홉킨스 유니버시티 신규의 생리적으로 유용한 니트록실 도너로서 n-히드록실술폰아미드 유도체
EP3067352A3 (en) 2008-05-07 2016-10-19 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
WO2011063339A1 (en) 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
US9018411B2 (en) * 2009-12-07 2015-04-28 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
AU2010328234B2 (en) 2009-12-07 2016-05-12 Cardioxyl Pharmaceuticals, Inc. N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
JP6177246B2 (ja) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ ヒドロキシルアミンで置換された、hno供与体としてのメルドラム酸、バルビツール酸、及びピラゾロンの誘導体
JP6449171B2 (ja) 2013-01-18 2019-01-09 カルディオキシル ファーマシューティカルズ,インク. 治療指数の改善されたニトロキシル供与体
US9682938B2 (en) 2014-05-27 2017-06-20 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
EP3148983A1 (en) 2014-05-27 2017-04-05 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors

Also Published As

Publication number Publication date
KR20140107197A (ko) 2014-09-04
CN104053647A (zh) 2014-09-17
CN104053647B (zh) 2018-06-01
KR102061537B1 (ko) 2020-01-03
WO2013059194A1 (en) 2013-04-25
US9499511B2 (en) 2016-11-22
CA2852914C (en) 2019-11-26
US9862699B2 (en) 2018-01-09
US20160115148A1 (en) 2016-04-28
US20170050947A1 (en) 2017-02-23
JP6177246B2 (ja) 2017-08-09
IL232101A0 (en) 2014-05-28
AU2013201929B2 (en) 2015-07-23
CA2852914A1 (en) 2013-04-25
MX363306B (es) 2019-03-20
SG11201401587QA (en) 2014-07-30
BR112014009282A8 (pt) 2020-04-22
JP2015501308A (ja) 2015-01-15
US20140275134A1 (en) 2014-09-18
US9181213B2 (en) 2015-11-10
AU2015246114A1 (en) 2015-11-12
BR112014009282B1 (pt) 2021-12-14
CN108409662B (zh) 2021-10-26
MX2014004596A (es) 2014-09-04
IL232101A (en) 2017-04-30
CN108409662A (zh) 2018-08-17
EP2776402B1 (en) 2017-07-26
EP2776402A1 (en) 2014-09-17
BR112014009282A2 (pt) 2017-06-13
AU2013201929A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
HK1200168A1 (en) Meldrum s acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors hno
IL261372A (en) Preparations, uses and solid forms of obeticholic acid
HK1210778A1 (en) Pyrimidine pyrazolyl derivatives
HK1202774A1 (en) Isoxazoline derivatives used in the control of ectoparasites
SG11201507272RA (en) Nuclei acid amplification
CO6811861A2 (es) Composición que comprende aflibercept, ácido folínico, 5-fluorouracilo (5-fu) e irinocetan (folfiri)
IL250370A0 (en) Propionic acid derivatives substituted with heteroaroylamino in position 3 and their use as pharmaceuticals
EP2875024A4 (en) HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES
IL249826A0 (en) Propionic acid derivatives converted in 3-heteroylamino and their use in pharmaceutical preparations
HK1188214A1 (zh) 二氨基嘧啶衍生物及其製備方法
EP2763998A4 (en) TRI-HETEROCYCLIC DERIVATIVES, MANUFACTURING METHOD AND USES THEREOF
EP2787002A4 (en) OLEANOIC ACID AMIDATE DERIVATIVES, METHOD OF MANUFACTURE AND ITS USE
EP2766501A4 (en) NUCLEIC ACID AMPLIFICATION AND USE THEREOF
IL248698B (en) History of 1-h-pyrrolidine-4,2-dione and processes for their preparation
EP2805956A4 (en) GAMBOGIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF
EP3068400A4 (en) Methods for reducing uric acid levels using barbiturate derivatives
IL240447A (en) Propionic Acid-Baryl Acid Derivatives and Their Use as Pharmaceutical Preparations
IL240422A0 (en) Bi-aryl derivatives of propionic acid and their use as medicinal preparations
AU2011100053A4 (en) Online Depreciation System and associated formulae and Processes
GB201115851D0 (en) Thermally stable rivet
PT2584008E (pt) Corantes de ácidos trisazo à base de naftóis
AU2012901711A0 (en) Per-processor queues